Your browser doesn't support javascript.
loading
Cancer Associated Fibroblasts Promote Renal Cancer Progression Through a TDO/Kyn/AhR Dependent Signaling Pathway.
Chen, Li-Bo; Zhu, Shun-Ping; Liu, Tian-Pei; Zhao, Heng; Chen, Ping-Feng; Duan, You-Jun; Hu, Rong.
Afiliação
  • Chen LB; Department of Urology, The First Affiliated Hospital of University of South China, Hengyang, China.
  • Zhu SP; Department of Respiratory, The First Affiliated Hospital of University of South China, Hengyang, China.
  • Liu TP; Department of Urology, The First Affiliated Hospital of University of South China, Hengyang, China.
  • Zhao H; Department of Radiology, The First Affiliated Hospital of University of South China, Hengyang, China.
  • Chen PF; Department of Urology, The First Affiliated Hospital of University of South China, Hengyang, China.
  • Duan YJ; Department of Urology, The First Affiliated Hospital of University of South China, Hengyang, China.
  • Hu R; Department of Radiology, The First Affiliated Hospital of University of South China, Hengyang, China.
Front Oncol ; 11: 628821, 2021.
Article em En | MEDLINE | ID: mdl-33842334
ABSTRACT
Cancer associated fibroblasts (CAFs) play crucial roles in cancer development, however, the specific mechanisms of CAFs associated renal cancer progression remain poorly understood. Our study observed enriched CAFs in high degree malignant tumor tissues from renal cancer patients. These CAFs isolated from tumor tissues are prone to facilitate drugs resistance and promote tumor progression in vitro and in vivo. Mechanistically, CAFs up-regulated tryptophan 2, 3-dioxygenase (TDO) expression, resulting in enhanced secretion of kynurenine (Kyn). Kyn produced from CAFs could up-regulated the expression of aromatic hydrocarbon receptor (AhR), eventually resulting in the AKT and STAT3 signaling pathways activation. Inhibition of AKT signal prevented cancer cells proliferation, while inhibition of the STAT3 signal reverted drugs resistance and cancer migration induced by kynurenine. Application of AhR inhibitor DMF could efficiently suppress distant metastasis of renal cancer cells, and improve anticancer effects of sorafenib (Sor)/sunitinib (Sun), which described a promising therapeutic strategy for clinical renal cancer.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Risk_factors_studies Idioma: En Revista: Front Oncol Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Risk_factors_studies Idioma: En Revista: Front Oncol Ano de publicação: 2021 Tipo de documento: Article